share_log

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals | 8-K:Shuttle Pharmaceuticals獲FDA批准繼續進行Ropidoxuridine治療膠質母細胞瘤患者II期臨床試驗
SEC announcement ·  01/08 00:00
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息